Pharmacokinetics, Metabolism and Interactions of Acid Pump Inhibitors

[1]  T. Andersson,et al.  The effect of oral omeprazole on the disposition of lignocaine , 1994, Anaesthesia.

[2]  D. Nebert,et al.  Cytochrome P450: evolution and functional diversity. , 1994, Progress in liver diseases.

[3]  J. Connell,et al.  Dose related in vitro effects of ranitidine and cimetidine on basal and ACTH-stimulated steroidogenesis. , 1986, Gut.

[4]  T. Andersson,et al.  Pharmacokinetics of [14C] omeprazole in patients with impaired renal function , 1986, Clinical pharmacology and therapeutics.

[5]  L. Wienkers,et al.  Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[6]  G R Wilkinson,et al.  The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.

[7]  P. Beaune,et al.  The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. , 1989, British journal of clinical pharmacology.

[8]  D. Colin-Jones.  Safety of lansoprazole , 1993, British journal of clinical practice. Supplement.

[9]  J. Miners,et al.  Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. , 1993, British journal of clinical pharmacology.

[10]  L. Bertilsson,et al.  Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S‐mephenytoin, but not debrisoquin, hydroxylation phenotype , 1989, Clinical pharmacology and therapeutics.

[11]  P. Höglund,et al.  Stereoselective Interaction of Omeprazole with Warfarin in Healthy Men , 1989, Therapeutic drug monitoring.

[12]  M. O'Mahony,et al.  Age, environmental factors and drug metabolism. , 1994, Pharmacology & therapeutics.

[13]  T. Sullivan,et al.  Absence of an inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker of CYP2C activity. , 1993, British journal of clinical pharmacology.

[14]  T. Andersson,et al.  A study of the interaction between omeprazole and cyclosporine in renal transplant patients. , 1993, British journal of clinical pharmacology.

[15]  A. Blum,et al.  Effects of omeprazole and lansoprazole on 24-hour intragastric pH in Helicobacter pylori-positive volunteers. , 1994, Scandinavian journal of gastroenterology.

[16]  J. Goldstein,et al.  Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. , 1993, Molecular pharmacology.

[17]  A. Richens,et al.  Oral phenytoin pharmacokinetics during omeprazole therapy. , 1987, British journal of clinical pharmacology.

[18]  A. Parkinson,et al.  Omeprazole and the induction of human cytochrome P-450: a response to concerns about potential adverse effects. , 1991, Gastroenterology.

[19]  R. Bergstrand,et al.  Omeprazole treatment does not affect the metabolism of caffeine. , 1991, Gastroenterology.

[20]  R. Pounder,et al.  Twenty‐four‐hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole , 1987, Alimentary pharmacology & therapeutics.

[21]  C. K. Stead,et al.  Quinidine single dose pharmacokinetics and pharmacodynamics are unaltered by omeprazole , 1991, Alimentary pharmacology & therapeutics.

[22]  J. Miners,et al.  In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase. , 1994, British journal of clinical pharmacology.

[23]  D. Kroetz,et al.  Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. , 1994, Biochemical pharmacology.

[24]  A. Conney,et al.  Stimulatory effect of brussels sprouts and cabbage on human drug metabolism , 1979, Clinical pharmacology and therapeutics.

[25]  R. Kato,et al.  Hepatic microsomal tolbutamide hydroxylation in Japanese: in vitro evidence for rapid and slow metabolizers. , 1993, Pharmacogenetics.

[26]  S. Meuwissen,et al.  Lack of effect of antacids on plasma concentrations of omeprazole given as enteric-coated granules. , 1987, British journal of clinical pharmacology.

[27]  A. Conney,et al.  Effect of cigarette smoking on phenacetin metabolism , 1974, Clinical pharmacology and therapeutics.

[28]  R. Gugler,et al.  Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. , 1985, Gastroenterology.

[29]  T. Kamataki,et al.  Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation. , 1993, The Journal of pharmacology and experimental therapeutics.

[30]  H. Wynne,et al.  Hepatic drug clearance: the effect of age using indocyanine green as a model compound. , 1990, British journal of clinical pharmacology.

[31]  C. Wolf,et al.  Differences in the cytochrome P-450 isoenzymes involved in the 2-hydroxylation of oestradiol and 17 alpha-ethinyloestradiol. Relative activities of rat and human liver enzymes. , 1990, The Biochemical journal.

[32]  A. Cohen,et al.  Influence of gastric acidity on the bioavailability of digoxin. , 1991, Annals of internal medicine.

[33]  D. V. van Thiel,et al.  Hypothalamic-pituitary-gonadal dysfunction in men using cimetidine. , 1979, The New England journal of medicine.

[34]  J. Miners,et al.  Co-regulation of phenytoin and tolbutamide metabolism in humans. , 1992, British journal of clinical pharmacology.

[35]  P. Lindberg,et al.  The mechanism of action of the gastric acid secretion inhibitor omeprazole. , 1986, Journal of medicinal chemistry.

[36]  S. Landahl,et al.  Renal function in an elderly population. A study of S-creatinine, 51Cr-EDTA clearance, endogenous creatinine clearance and maximal tubular water reabsorption. , 1986, Scandinavian journal of clinical and laboratory investigation.

[37]  H. Ostensen,et al.  The incidence of peptic ulcer disease related to occupation in the northern part of Norway. A prospective epidemiological and radiological study. , 1985, Scandinavian journal of gastroenterology.

[38]  J. Brockmöller,et al.  Assessment of Liver Metabolic Function , 1994, Clinical pharmacokinetics.

[39]  T. Andersson,et al.  Bioavailability of Omeprazole as Enteric Coated (EC) Granules in Conjunction with Food on the First and Seventh Days of Treatment , 1990 .

[40]  K. Brøsen,et al.  A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man. , 1990, British journal of clinical pharmacology.

[41]  J. Miners,et al.  Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. , 1994, British journal of clinical pharmacology.

[42]  T. Andersson.  Omeprazole Drug Interaction Studies , 1991, Clinical pharmacokinetics.

[43]  K. Anderson,et al.  Enhanced phenacetin metabolism in human subjects fed charcoal‐broiled beef , 1976, Clinical pharmacology and therapeutics.

[44]  F. Guengerich,et al.  Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. , 1991, Chemical research in toxicology.

[45]  J. Miners,et al.  Characterisation of theophylline metabolism by human liver microsomes. Inhibition and immunochemical studies. , 1988, Biochemical pharmacology.

[46]  M. J. Coon,et al.  The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. , 1993, DNA and cell biology.

[47]  U. Klotz,et al.  Lansoprazole does not affect the bioavailability of oral contraceptives. , 1994, British journal of clinical pharmacology.

[48]  G. Ekenved,et al.  Bioavailability studies on a buffered acetylsalicylic acid preparation. , 1975, Acta pharmaceutica Suecica.

[49]  T. Andersson,et al.  Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. , 1991, British journal of clinical pharmacology.

[50]  M. Lennard,et al.  Defective metabolism of metoprolol in poor hydroxylators of debrisoquine. , 1982, British journal of clinical pharmacology.

[51]  P. Lindberg,et al.  Chemical Reactions of Omeprazole and Omeprazole Analogues. I. A Survey of the Chemical Transformations of Omeprazole and its Analogues. , 1989 .

[52]  J. Brockmöller,et al.  Increase of cytochrome P450IA2 activity by omeprazole: Evidence by the 13C‐[N‐3‐methyl]‐caffeine breath test in poor and extensive metabolizers of S‐mephenytoin , 1992, Clinical pharmacology and therapeutics.

[53]  E. Perucca,et al.  Omeprazole Does Not Enhance the Metabolism of Phenacetin, a Marker of CYP1A2 Activity, in Healthy Volunteers , 1994, Therapeutic drug monitoring.

[54]  W. Wurst,et al.  Lack of influence of pantoprazole on the disposition kinetics of theophylline in man. , 1991, International journal of clinical pharmacology, therapy, and toxicology.

[55]  T. Andersson,et al.  The Pharmacokinetics of Omeprazole in Humans—A Study of Single Intravenous and Oral Doses , 1990, Therapeutic drug monitoring.

[56]  F. Guengerich,et al.  Oxidation of quinidine by human liver cytochrome P-450. , 1986, Molecular pharmacology.

[57]  E. Greisheimer.  Physiology of the alimentary tract. , 1952, Journal of the American Medical Women's Association.

[58]  Yuan Zhang,et al.  Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. , 1992, Pharmacogenetics.

[59]  A. Pilbrant,et al.  Development of an oral formulation of omeprazole. , 1985, Scandinavian journal of gastroenterology. Supplement.

[60]  F. Guengerich,et al.  Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. , 1991, The Journal of pharmacology and experimental therapeutics.

[61]  C. Bonfils,et al.  Oxidative metabolism of lansoprazole by human liver cytochromes P450. , 1995, Molecular pharmacology.

[62]  H. Wynne,et al.  Age-Related Changes in Hepatic Function , 1992, Drugs & aging.

[63]  M. Regazzi,et al.  Pharmacokinetics of omeprazole in cirrhotic patients. , 1991, Arzneimittel-Forschung.

[64]  W. Wurst,et al.  Lack of interaction between pantoprazole and digoxin at therapeutic doses in man. , 1995, International journal of clinical pharmacology and therapeutics.

[65]  W. Wurst,et al.  Lack of pantoprazole drug interactions in man. , 1994, International journal of clinical pharmacology and therapeutics.

[66]  T. Andersson,et al.  Pharmacokinetic Study of Omeprazole in Elderly Healthy Volunteers , 1992, Clinical pharmacokinetics.

[67]  T. Andersson,et al.  A study of the interaction of omeprazole and warfarin in anticoagulated patients. , 1992, British journal of clinical pharmacology.

[68]  B K Tang,et al.  Biotransformation of caffeine by microsomes from human liver. Kinetics and inhibition studies. , 1987, Biochemical pharmacology.

[69]  S. Toon,et al.  Effects of Cimetidine, Ranitidine and Omeprazole on Tolbutamide Pharmacokinetics , 1995 .

[70]  R. Gugler,et al.  Drugs other than H2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo. , 1987, Pharmacology & therapeutics.

[71]  I. Roots,et al.  Specific and dose‐dependent enzyme induction by omeprazole in human beings , 1994, Hepatology.

[72]  R. Schall,et al.  Effect of Pantoprazole on Ovulation Suppression by a Low-Dose Hormonal Contraceptive , 1995 .

[73]  E. Ganse,et al.  Influence of lansoprazole treatment on diazepam plasma concentrations , 1992, Clinical pharmacology and therapeutics.

[74]  R. Bergstrand,et al.  Decreased Oral Bioavailability of Lansoprazole in Healthy Volunteers when Given with a Standardised Breakfast , 1995 .

[75]  B. Flouvat,et al.  The effect of food and antacids on lansoprazole absorption and disposition. , 1991, European journal of drug metabolism and pharmacokinetics.

[76]  B. Flouvat,et al.  Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. , 1993, British journal of clinical pharmacology.

[77]  R. Schall,et al.  Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. , 1995, British journal of clinical pharmacology.

[78]  J. Michnovicz,et al.  Omeprazole fails to alter the cytochrome P450-dependent 2-hydroxylation of estradiol in male volunteers. , 1993, Pharmacology.

[79]  J. Miners,et al.  Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. , 1991, British journal of clinical pharmacology.

[80]  G. Beastall,et al.  Inhibition by omeprazole of adrenocortical response to ACTH: clinical studies and experiments on bovine adrenal cortex in vitro. , 1986, Clinical science.

[81]  D. Stevens,et al.  Ketoconazole blocks adrenal steroid synthesis. , 1982, Annals of internal medicine.

[82]  L. Bertilsson,et al.  Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. , 1990, Therapeutic drug monitoring.

[83]  Jerome J. Schentag,et al.  Effects of ranitidine and sucralfate on ketoconazole bioavailability , 1991, Antimicrobial Agents and Chemotherapy.

[84]  R. Edwards,et al.  A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. , 1988, British journal of clinical pharmacology.

[85]  G. Sachs,et al.  Continuing development of acid pump inhibitors: site of action of pantoprazole. , 1994, Alimentary pharmacology & therapeutics.

[86]  J. Miners,et al.  Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. , 1994, British journal of clinical pharmacology.

[87]  H. Balks,et al.  The effects of lansoprazole, 30 or 60 mg daily, on intragastric pH and on endocrine function in healthy volunteers , 1993, Alimentary pharmacology & therapeutics.

[88]  T. Andersson,et al.  No Influence of Single Intravenous Doses of Omeprazole on Theophylline Elimination Kinetics , 1992, Journal of clinical pharmacology.

[89]  G. Tucker,et al.  The interaction of proton pump inhibitors with cytochromes P450. , 1994, Alimentary pharmacology & therapeutics.

[90]  L. Benet,et al.  Pharmacokinetics‐‐a relevant factor for the choice of a drug? , 1994, Alimentary Pharmacology and Therapeutics.

[91]  P. Beaune,et al.  Nature of cytochromes P450 involved in the 2-/4-hydroxylations of estradiol in human liver microsomes. , 1992, Biochemical pharmacology.

[92]  T. Andersson,et al.  Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. , 1994, Therapeutic drug monitoring.

[93]  T. Adrian,et al.  Effect of single dose of omeprazole on the gastrointestinal peptide response to food. , 1984, Hepato-gastroenterology.

[94]  K. Chiba,et al.  Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation recruited from an Oriental population. , 1992, The Journal of pharmacology and experimental therapeutics.

[95]  P. Höglund,et al.  No effect of omeprazole-induced hypoacidity on the bioavailability of amoxycillin or bacampicillin. , 1989, Scandinavian journal of infectious diseases.

[96]  S. Kitareewan,et al.  Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. , 1994, Biochemistry.

[97]  L. Kaminsky,et al.  Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. , 1995, Biochemical pharmacology.

[98]  G. Sachs,et al.  Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+) ATPase , 1981, Nature.

[99]  U. Haglund,et al.  Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man. , 1983, Gut.

[100]  U. Meyer,et al.  Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4 , 1989, Clinical pharmacology and therapeutics.

[101]  A. Gent,et al.  Adhesive and hydrophobic properties of Escherichia coli from the rectal mucosa of patients with ulcerative colitis. , 1993, Gut.

[102]  M. Mayersohn.  Chapter 8 Physiological Factors that Modify Systemic Drug Availability and Pharmacologic Response in Clinical Practice , 1978 .

[103]  O. Garden,et al.  The anti‐secretory effect and pharmacokinetics of omeprazole in chronic liver disease , 1988, Alimentary pharmacology & therapeutics.

[104]  B. Brodie,et al.  Principles and perspectives in drug bioavailability , 1979 .

[105]  W. Londong.  Effect of pantoprazole on 24‐h intragastric pH and serum gastrin in humans. , 1994, Alimentary pharmacology & therapeutics.

[106]  T. Andersson,et al.  Pharmacokinetics of [14C]Omeprazole in Patients with Liver Cirrhosis , 1993, Clinical pharmacokinetics.

[107]  M. Lai,et al.  Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6 , 1993, Clinical pharmacology and therapeutics.

[108]  P. Lundborg,et al.  Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole , 1990, Clinical pharmacology and therapeutics.

[109]  O. Mcbride,et al.  Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. , 1988, DNA.

[110]  P. Guzelian,et al.  Characterization of human liver cytochromes P-450 involved in theophylline metabolism. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[111]  R. Luehmann,et al.  Effects of pantoprazole on endocrine function in healthy male volunteers , 1994, Alimentary pharmacology & therapeutics.

[112]  M. Relling,et al.  Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. , 1990, The Journal of pharmacology and experimental therapeutics.

[113]  E. D. Jacobson,et al.  Histamine H1- and H2-receptor vasodilation of canine intestinal circulation. , 1977, The American journal of physiology.

[114]  K. Tolman,et al.  Effect of Lansoprazole on Male Hormone Function , 1994 .

[115]  C. Regårdh,et al.  Pharmacokinetics and metabolism of omeprazole in animals and man--an overview. , 1985, Scandinavian journal of gastroenterology. Supplement.

[116]  R. Branch,et al.  Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities , 1989, Clinical pharmacology and therapeutics.

[117]  G. Sachs,et al.  The continuing development of proton pump inhibitors with particular reference to pantoprazole , 1995, Alimentary pharmacology & therapeutics.

[118]  Immediate Effect of Omeprazole and Cimetidine on Apparent Liver Blood Flow in Man , 1986 .

[119]  C. Funck-Brentano,et al.  Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans , 1992, Clinical pharmacology and therapeutics.

[120]  T. Andersson,et al.  A Study of the Interaction Between Omeprazole and Phenytoin in Epileptic Patients , 1990, Therapeutic drug monitoring.

[121]  J. Kolars,et al.  Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[122]  R. Schall,et al.  No influence of pantoprazole on the pharmacokinetics of phenytoin. , 1995, International journal of clinical pharmacology and therapeutics.

[123]  G. Granneman,et al.  Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. , 1993, British journal of clinical pharmacology.

[124]  Ajit Kumar,et al.  Effect of Multiple Dose Omeprazole on the Pharmacokinetics of Carbamazepine , 1994 .

[125]  F. Sundler,et al.  Lansoprazole and omeprazole have similar effects on plasma gastrin levels, enterochromaffin-like cells, gastrin cells and somatostatin cells in the rat stomach. , 1992, Digestion.

[126]  L. Benet,et al.  The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine , 1995, Clinical pharmacology and therapeutics.

[127]  J. Schuetz,et al.  Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. , 1994, Pharmacogenetics.

[128]  T. Kronbach,et al.  Cyclosporine metabolism in human liver: Identification of a cytochrome P‐450III gene family as the major cyclosporine‐metabolizing enzyme explains interactions of cyclosporine with other drugs , 1988, Clinical pharmacology and therapeutics.

[129]  L. Bertilsson,et al.  No Effect on Plasma Carbamazepine Concentration with Concomitant Omeprazole Treatment , 1995 .

[130]  J. Kolars,et al.  Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. , 1992, The Journal of clinical investigation.